Cellectis Granted Patent for CRISPR Use in T-Cells – Markets Insider
|
Cellectis Granted Patent for CRISPR Use in T-Cells
Markets Insider EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells. The patent will be issued on August 2, 2017. This therapeutic-focused patent follows previous intellectual property that … |
